Replies to post #348 on Proteostasis Therapeutics Inc (PTI)

[Dallas-Cowboys]

PTI rose today because of this.

"Proteostasis data more positive than perceived, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein believes the Phase 2 data reported last week by Proteostasis (PTI) are more positive than the Street perceives. Although the 8% mean ppFEV1 improvement fell short of the perceived bar of 10% in cystic fibrosis, treatment, this level of benefit is nevertheless approvable, Fein tells investors in a research note. At the very least, Proteostasis' triple regimen could be used in patients who don't have access to, and those who are not experiencing a significant improvement with the Vertex (VRTX) regimens, says the analyst. He reiterates a Buy rating on Proteostasis with an $8 price target. The company's story "only gets more interesting from here, with more associated upside than downside," says Fein."